Skip to main content

Market Overview

Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies

  • Akari Therapeutics Plc (NASDAQ: AKTXannounces new data from PASylated nomacopan published in the journal CELLS.
  • In a non-infectious allergic uveitis animal model, PAS-nomacopan reduced VEGF by more than 50% compared to saline control, equivalent to the inhibition caused by an anti-VEGF antibody.
  • Separately, Akari recently completed a preclinical study in which intravitreally injected PAS-nomacopan was compared to Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eyelea, an FDA-approved treatment for wet AMD.
  • PAS-nomacopan injected once during the 16-day treatment period was equivalent to Eyelea in reducing neo-vascularisation.
  • The company says that PAS-nomacopan was significantly more effective in reducing retinal inflammation than the anti-VEGF antibody.
  • PAS-nomacopan's optimal dose interval to be used in clinical trials is yet to be determined.
  • Price Action: AKTX shares are 0.58% higher at $3.48 in market trading hours on the last check Thursday.

Related Articles (AKTX)

View Comments and Join the Discussion!

Posted-In: Biotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at